Login / Signup

Tuning protein synthesis for cancer therapy.

John R P KnightOwen J Sansom
Published in: Molecular & cellular oncology (2021)
~50% of colorectal cancers have an activating mutation in KRAS (encoding the KRAS proto-oncogene) and remain difficult to target in the clinic. We have recently shown that activation of KRAS protein alters the regulation of mRNA translation, increasing total protein synthesis, and maintaining elevated c-MYC (MYC proto-oncogene) expression. Targeting these pathways downstream of KRAS reveals a striking dependency that has potential for clinical translation.
Keyphrases
  • cancer therapy
  • wild type
  • binding protein
  • poor prognosis
  • drug delivery
  • primary care
  • signaling pathway
  • transcription factor
  • risk assessment
  • young adults
  • human health